Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2

Area of Science:

• Immunology
• Nanotechnology
• Endocrinology

Background:

• Type 1 diabetes (T1D) is an autoimmune disease targeting pancreatic beta cells, driven by T cells.
• Current cell-based therapies for T1D, like regulatory T cells and tolerogenic dendritic cells, face clinical translation challenges.
• Restoring immune tolerance is a key therapeutic goal for T1D and other autoimmune conditions.

Purpose of the Study:

• To engineer nanoparticles (NPs) for delivering tolerogenic molecules and beta cell antigens to induce immune tolerance in vivo.
• To evaluate the therapeutic potential of these NPs in a mouse model of autoimmune diabetes.

Main Methods:

• Developed nanoparticles (NPITE+Ins) encapsulating an aryl hydrocarbon receptor ligand (ITE) and proinsulin.
• Administered NPITE+Ins to nonobese diabetic mice.
• Assessed DC phenotype, T cell activation, regulatory T cell (Treg) differentiation, and diabetes suppression.

Main Results:

• NPITE+Ins administration suppressed autoimmune diabetes in mice.
• Induced a tolerogenic phenotype in dendritic cells (DCs), characterized by reduced inflammatory T cell activation and increased Treg differentiation.
• NP-mediated DC tolerogenicity was linked to aryl hydrocarbon receptor-dependent Socs2 induction, inhibiting NF-κB activation and pro-inflammatory cytokine production.

Conclusions:

• Engineered nanoparticles can effectively deliver tolerogenic signals and antigens to reestablish immune tolerance.
• This NP-based strategy shows potential for treating type 1 diabetes and other autoimmune disorders.
• Nanoparticles offer a promising, clinically translatable platform for autoimmune disease therapy.